Metabolic syndrome contributes to an increased recurrence risk of non-metastatic colorectal cancer

Oncotarget

Volumn 6, Issue 23, 2015, Pages 19880-19890

  You, Jie ^a   Liu, Wen Yue ^a   Zhu, Gui Qi ^a,b   Wang, Ou Chen ^a   Ma, Rui Min ^a   Huang, Gui Qian ^a,b   Shi, Ke Qing ^a,b   Guo, Gui Long ^a   Braddock, Martin ^c   Zheng, Ming Hua ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ASTRAZENECA   (United Kingdom)

Author keywords

Disease free survival; Metabolic syndrome; Non metastatic colorectal cancer; Overall survival; Risk factor

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; URIC ACID;

AGE; AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER RECURRENCE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; KAPLAN MEIER METHOD; LOCAL METASTASIS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON METASTATIC COLORECTAL CANCER; OBESITY; OVERALL SURVIVAL; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; CHI SQUARE DISTRIBUTION; CHINA; COLORECTAL NEOPLASMS; COMORBIDITY; DISEASE COURSE; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; CHI-SQUARE DISTRIBUTION; CHINA; COLORECTAL NEOPLASMS; COMORBIDITY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84939231683     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4166     Document Type: Article

References (38)

1. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014; 383:1490-1502.
2. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:104-117.
3. Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, Lopez-Calvino B, Seoane-Pillado T, Pertega-Diaz S. Intensive follow-up strategies improve outcomes in non-metastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2015; 26:644-656.
4. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988; 37:1595-1607.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Jama. 2002; 287:356-359.
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640-1645.
7. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet. 2005; 365:1398-1405.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106:3143-3421.
9. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371:569-578.
10. Sax AT, Jenkins DG, Devin JL, Hughes GI, Bolam KA, Skinner TL. The insulin-like growth factor axis: A biological mechanism linking physical activity to colorectal cancer survival. Cancer epidemiology. 2014; 38:455-459.
11. Lee JS, Cho SI, Park HS. Metabolic syndrome and cancer-related mortality among Korean men and women. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2010; 21:640-645.
12. Jaggers JR, Sui X, Hooker SP, LaMonte MJ, Matthews CE, Hand GA, Blair SN. Metabolic syndrome and risk of cancer mortality in men. Eur J Cancer. 2009; 45:1831-1838.
13. Yang Y, Mauldin PD, Ebeling M, Hulsey TC, Liu B, Thomas MB, Camp ER, Esnaola NF. Effect of metabolic syndrome and its components on recurrence and survival in colon cancer patients. Cancer. 2013; 119:1512-1520.
14. Shen Z, Wang S, Ye Y, Yin M, Yang X, Jiang K, Liu Y. Clinical study on the correlation between metabolic syndrome and colorectal carcinoma. ANZ journal of surgery. 2010; 80:331-336.
15. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer. 2006; 107:28-36.
16. Jinjuvadia R, Lohia P, Jinjuvadia C, Montoya S, Liangpunsakul S. The association between metabolic syndrome and colorectal neoplasm: systemic review and meta-analysis. Journal of clinical gastroenterology. 2013; 47:33-44.
17. Trevisan M, Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. American journal of epidemiology. 1998; 148:958-966.
18. Trevisan M, Liu J, Muti P, Misciagna G, Menotti A, Fucci F. Markers of insulin resistance and colorectal cancer mortality. Cancer epidemiology, biomarkers&prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001; 10:937-941.
19. Colangelo LA, Gapstur SM, Gann PH, Dyer AR, Liu K. Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2002; 11:385-391.
20. Yao X, Tian Z. Dyslipidemia and colorectal cancer risk: a meta-analysis of prospective studies. Cancer causes & control: CCC. 2015; 26:257-268.
21. Agnoli C, Grioni S, Sieri S, Sacerdote C, Vineis P, Tumino R, Giurdanella MC, Pala V, Mattiello A, Chiodini P, Iacoviello L, De Curtis A, Cattaneo L, et al. Colorectal cancer risk and dyslipidemia: a case-cohort study nested in an Italian multicentre cohort. Cancer epidemiology. 2014; 38:144-151.
22. Liu YL, Qian HX, Qin L, Zhou XJ, Zhang B. Serum LDL-C and LDL-C/HDL-C ratio are positively correlated to lymph node stages in males with colorectal cancer. Hepatogastroenterology. 2011; 58:383-387.
23. Berrino F, Villarini A, Traina A, Bonanni B, Panico S, Mano MP, Mercandino A, Galasso R, Barbero M, Simeoni M, Bassi MC, Consolaro E, Johansson H, et al. Metabolic syndrome and breast cancer prognosis. Breast cancer research and treatment. 2014; 147:159-165.
24. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer research. 2008; 68:329-337.
25. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27:176-185.
26. Aleksandrova K, Nimptsch K, Pischon T. Influence of Obesity and Related Metabolic Alterations on Colorectal Cancer Risk. Current nutrition reports. 2013; 2:1-9.
27. Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G, Ferroni P. Obesity-driven inflammation and colorectal cancer. Current medicinal chemistry. 2012; 19:5837-5853.
28. Hamilton TD, Leugner D, Kopciuk K, Dixon E, Sutherland FR, Bathe OF. Identification of prognostic inflammatory factors in colorectal liver metastases. BMC cancer. 2014; 14:542.
29. Lin M, Huang J, Zhu J, Shen H. Elevated pre-treatment levels of high sensitivity C-reactive protein as a potential prognosticator in patients with colorectal cancer. Experimental and therapeutic medicine. 2013; 6:1369-1374.
30. Shibutani M, Maeda K, Nagahara H, Ohtani H, Sugano K, Ikeya T, Kimura K, Amano R, Kubo N, Tanaka H, Muguruma K, Ohira M, Hirakawa K. Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer. Hepatogastroenterology. 2014; 61:2236-2240.
31. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A, Overvad K, Toft-Petersen AP, Tjonneland A, Hansen L, Boutron-Ruault MC, et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut. 2011; 60:1094-1102.
32. Kontou N, Psaltopoulou T, Soupos N, Polychronopoulos E, Xinopoulos D, Linos A, Panagiotakos DB. Metabolic syndrome and colorectal cancer: the protective role of Mediterranean diet-a case-control study. Angiology. 2012; 63:390-396.
33. Esposito K, Marfella R, Ciotola M, Di Palo C, Giugliano F, Giugliano G, D'Armiento M, D'Andrea F, Giugliano D. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. Jama. 2004; 292:1440-1446.
34. Stevens RJ, Ali R, Bankhead CR, Bethel MA, Cairns BJ, Camisasca RP, Crowe FL, Farmer AJ, Harrison S, Hirst JA, Home P, Kahn SE, McLellan JH, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012; 55:2593-2603.
35. Jansen L, Below J, Chang-Claude J, Brenner H, Hoffmeister M. Beta blocker use and colorectal cancer risk: population-based case-control study. Cancer. 2012; 118:3911-3919.
36. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2010; 116:3389-3398.
37. Siddiqui AA, Nazario H, Mahgoub A, Patel M, Cipher D, Spechler SJ. For patients with colorectal cancer, the long-term use of statins is associated with better clinical outcomes. Digestive diseases and sciences. 2009; 54:1307-1311.
38. Aykan AC, Gul I, Kalaycioglu E, Gokdeniz T, Hatem E, Mentese U, Yildiz BS, Yildiz M. Is metabolic syndrome related with coronary artery disease severity and complexity: An observational study about IDF and AHA/NHLBI metabolic syndrome definitions. Cardiology journal. 2014; 21:245-251.